ASCO 2018 – Monday, June 4

Monday, June 4

8-11:30 a.m.
Hall A
POSTER SESSIONS:
Inotuzumab ozogamicin (InO) treatment in patients
with relapsed/refractory (R/R) acute lymphoblastic
leukemia (ALL): analysis from INO-VATE by bone
marrow blast percentage (BMB%)
Poster #88; Abstract 7028
Anjali S. Advani, MD – First Author

Phase 3, randomized, placebo-controlled trials
evaluating glasdegib in combination with intensive
or nonintensive chemotherapy in patients with
untreated acute myeloid leukemia
Poster #133a; Abstract TPS7073
Mikkael Sekeres, MD, MS – Author

Phase 3 study of first line pevonedistat (PEV) +
azacitidine (AZA) versus single-agent AZA in patients
with higher-risk myelodysplastic syndromes (HR
MDS), chronic myelomonocytic leukemia (CMML) or
low-blast acute myelogenous leukemia (AML)
Poster #135a; Abstract TPS7077
Mikkael Sekeres, MD, MS – First author

Quality of life in patients with advanced renal cell
carcinoma in the randomized, open-label CheckMate 214 trial
Poster #287; Abstract 3073
Brian Rini, MD – Author

8:40-9 a.m.
E451
EDUCATION SESSION:
Cancer Stem Cells: Untangling the Controversies,
Rationalizing the Treatments
Ultimate precision: targeting cancer but not normal self-replication
Yogen Saunthararajah, MD – Speaker

8:48-9 a.m.
S102
CLINICAL SCIENCE SYMPOSIUM:
Tumor Testing in Precision Oncology: From
Heredity to Counseling to Implementation
Genetic counseling (GC) and germline (GL) testing
rates after adoption of an integrated clinical
cancer genetics (CCG) approach to genomics tumor board (GTB)
Abstract 1511
Stefan Klek – Speaker

9:45-11:15 a.m.
E451
CLINICAL SCIENCE SYMPOSIUM:
Innovative Immune and Genomic Biomarkers for Solid Tumors
Vamsidhar Velcheti, MD – Chair

11:30 a.m. – 12:45 p.m.
E450
POSTER DISCUSSION SESSION:
Hematologic Malignancies — Leukemia,
Myelodysplastic Syndromes and Allotransplant
Anjali S. Advani, MD – Chair

1:15-4:45 p.m.
Hall A
POSTER SESSIONS:
PRC-2 epigenetic chromatin reprogramming in ALKpositive
(ALK+) lung cancer initial emergence of precision drug resistance
Poster #133; Abstract 12020
Vamsidhar Velcheti, MD – Author

Development of a comprehensive cell-free DNA
(cfDNA) assay for early detection of multiple tumor
types: the Circulating Cell-free Genome Atlas (CCGA) study
Poster #134; Abstract 12021
Eric Klein, MD – First author

Tumor PD-L1 heterogeneity in non-small cell lung
cancer: Does biopsy size and volume matter?
Poster #171; Abstract 12058
Monica Khunger, MD – First author; Vamsidhar
Velcheti, MD – Author

PD-1/PD-L1 interaction and CD25/FOXP3+
T cells predict survival benefit from adjuvant
chemotherapy in early stage non-small-cell lung
cancer (ES-NSCLC)
Poster #172; Abstract 12059
Vamsidhar Velcheti, MD – Author

Computer extracted features of cancer nuclei from
H&E stained tissues of tumor predicts response to
nivolumab in non-small cell lung cancer
Poster #174; Abstract 12061
Vamsidhar Velcheti, MD – Author

Computer-extracted features relating to spatial
arrangement of tumor infiltrating lymphocytes to
predict response to nivolumab in non-small cell lung cancer
Poster #228; Abstract 12115
Vamsidhar Velcheti, MD – Author

Treatment-free survival (TFS), a novel outcome
applied to immuno-oncology (IO) agents in advanced
melanoma (AM)
Poster #358; Abstract 9531
Ahmad Tarhini, MD, PhD – Author

Clinical and economic outcomes associated with
sequential treatment in BRAF-mutant advanced
melanoma patients
Poster #365; Abstract 9538
Ahmad Tarhini, MD, PhD – First author

Surveillance for melanoma (MEL): results of a
database study of stage 1-3 MEL
Poster #413; Abstract 9586
Ahmad Tarhini, MD, PhD – Author

1:15-1:35 p.m.
E253d
MEET THE PROFESSOR SESSION:
Perioperative Systemic Therapy for Localized
Renal Cell Carcinoma: To Treat or Not to Treat
Systemic therapy in management of high-risk renal cancer
Brian Rini, MD – Speaker

1:15-2:30 p.m.
Arie Crown Theater
EDUCATION SESSION:
Immunotherapy Beyond the Checkpoints: CARs,
Trucks and More
Vamsidhar Velcheti, MD – Chair

1:35-1:55 p.m.
Cytokines in cancer immunotherapy: recent updates
Vamsidhar Velcheti, MD – Speaker

1:55-2:15 p.m.
E451
EDUCATION SESSION:
Advances in Fertility Preservation for Young Women with Cancer
GnRH analogs for fertility preservation: What are the data?
Halle Moore, MD – Speaker

3-4:15 p.m.
S103
EDUCATION SESSION:
Patient-Clinician Communication Is a Two-Way
Street: Driving in Parallel Toward Well-Being
Timothy Gilligan, MD – Chair

3-3:20 pm
S103
Patient-clinician communication: implementing the
new ASCO consensus guideline
Timothy Gilligan, MD – Speaker

4:45-6 p.m.
S406
POSTER DISCUSSION SESSION:
Tumor Biology
4:45-4:57 p.m.
Overcoming Resistance to Immune Checkpoint Blockade
(Abstracts 12012, 12013, 12014, 12015)
Vamsidhar Velcheti, MD – Discussant

5:21-5:33 p.m.
Novel Molecular Analysis to Interrogate Tumor
Phenotypes: Epigenetics, miRNA and Beyond
(Abstracts 12018, 12019, 12020)
PRC-2 epigenetic chromatin reprogramming in ALKpositive
(ALK+) lung cancer initial emergence of
precision drug resistance
Abstract 12020
Vamsidhar Velcheti, MD – Author

5:39-5:51 p.m.
Resources and Tools for Precision Oncology:
cfDNA Genome Atlas and PDX Models
(Abstracts 12021, 12022, 12023)

Abstract 12021: Development of a comprehensive
cell-free DNA (cfDNA) assay for early detection
of multiple tumor types: The Circulating Cell-free
Genome Atlas (CCGA) study
Eric Klein, MD – First author